Skip to main content

Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis

Lead Author: Nicole Shuckett, RD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: November 2, 2022

Read more (opens new window)

Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration

Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: November 1, 2022

Read more (opens new window)

Reduced Plasma Concentration of the Neuroinflammation Biomarker Chitinase-3-Like Protein (CHI3L1/YKL-40) in the CENTAUR Trial

Lead Author: Robert Bowser, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: November 1, 2022

Read more (opens new window)

International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)

Lead Author: Leonard H. van den Berg, MD, PhD

Published: International Congress on Neuromuscular Diseases (ICNMD)

Date: July 9, 2022

Read more (opens new window)

Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results

Lead Author: Tracey Jason, PhD, Head of Medical Affairs at Amylyx Pharmaceuticals Canada

Published: Canadian Neurological Sciences Federation (CNSF)

Date: June 26, 2022

Read more (opens new window)

Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results

Lead Author: Lahar Mehta, MD, Head of Global Clinical Development at Amylyx Pharmaceuticals

Published: European Network to Cure ALS (ENCALS)

Date: June 2, 2022

Read more (opens new window)

Effect of Sodium Phenylbutyrate/Taurursodiol on Tracheostomy/Ventilation-Free Survival and Hospitalisation in Amyotrophic Lateral Sclerosis: Long-Term Results from the CENTAUR Trial

Lead Author: Sabrina Paganoni, MD, PhD

Published: Journal of Neurology, Neurosurgery and Psychiatry

Date: May 16, 2022

Read more (opens new window)

Survival Analyses from the CENTAUR Trial in Amyotrophic Lateral Sclerosis: Evaluating the Impact of Treatment Crossover on Outcomes

Lead Author: Sabrina Paganoni, MD, PhD

Published: Muscle & Nerve

Date: May 4, 2022

Read more (opens new window)

Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Integrated Clinical Trial Experience

Lead Author: Steven E. Arnold, MD

Published: American Academy of Neurology (AAN)

Date: April 4, 2022

Read more (opens new window)

Expanded Access to Sodium Phenylbutyrate/Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Learnings From an ALS Community Partnership

Lead Author: Machelle Manuel, PhD, Head of Global Medical Affairs at Amylyx Pharmaceuticals

Published: Muscular Dystrophy Association (MDA)

Date: March 13 - 16, 2022

Read more (opens new window)